Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.55 |
| ▸ | CLK1 | P49759 | 1/20 | 0.55 |
| ▸ | CDK9 | P50750 | 10/20 | 0.50 |
| ▸ | CDK1 | P06493 | 9/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.50 |
| ▸ | CDK7 | P50613 | 6/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.50 |
| ▸ | CCNH | P51946 | 5/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
| ▸ | FLT1 | P17948 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27664540 | 0.92 | CDK2 (0.51) | CDK2CLK1CDK9CDK1CCNT1 | |
| SCHEMBL2086771 | 0.90 | CDK2 (0.58) | CDK2CLK1CDK9CDK1CCNT1 | |
| SCHEMBL2086251 | 0.89 | CDK2 (0.54) | CDK2CLK1CDK9CDK1CCNT1 | |
| SCHEMBL2086940 | 0.88 | CDK2 (0.51) | CDK2CLK1CDK9CDK1CCNT1 | |
| SCHEMBL2086822 | 0.86 | CDK2 (0.59) | CDK2CLK1CDK9CDK1CCNT1 | |
| SCHEMBL2086222 | 0.85 | CDK2 (0.56) | CDK2CLK1CDK9CDK1CCNT1 | |
| SCHEMBL2086549 | 0.84 | CDK2 (0.53) | CDK2CLK1CDK9CDK1CCNT1 | |
| SCHEMBL2087887 | 0.84 | CDK1 (0.67) | CDK2CLK1CDK9CDK1CCNT1 | |
| SCHEMBL5136323 | 0.83 | CDK2 (0.47) | CDK2CLK1CDK9CDK1CCNT1 | |
| SCHEMBL2087333 | 0.83 | CDK2 (0.55) | CDK2CLK1CDK9CDK1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902361-B2 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2011-03-08 | — | — | US | claimed |
| JP-2007509117-A | — | — | 2007-04-12 | — | — | JP | claimed |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | claimed |
| EP-1678171-A1 | PYRIMIDIN-4-YL-3,4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2006-07-12 | — | — | EP | claimed |
| WO-2005042525-A1 | PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | claimed |
| EP-1678171-B1 | 2-AMINO-4-THIAZOLONE-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| US-7902361-B2 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| EP-1951307-A2 | COMBINATION OF A CDK-INHIBITOR AND A HDAC-INHIBITOR | Cyclacel Limited (GB) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007054725-A2 | COMBINATION OF A CDK-INHIBITOR AND A HDAC-INHIBITOR | CYCLACEL LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| CN-1898237-A | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LTD (GB) | 2007-01-17 | — | — | CN | disclosed |
| EP-1678171-A1 | PYRIMIDIN-4-YL-3,4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042525-A1 | PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | MSRB3, DHFR, CBR3 | CDK2 459/4885CLK1 2868/4885CDK9 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.